Sign up to save your data!
Some tips to help get started:
Processing...
There are 746 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
746 trials meet filter criteria.
Sort by:
HealthScout AI summary: Eligible patients are adults with locally advanced or metastatic non-small cell lung cancer harboring a KRAS G12C mutation and good performance status. The study is evaluating BBO-8520, a first-in-class dual ON/OFF KRAS G12C inhibitor, as monotherapy and in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT06343402
HealthScout AI summary: Eligible patients are adults with locally advanced or metastatic solid tumors harboring a KRAS G12D mutation, who have progressed on or are intolerant to standard therapies and meet organ function and performance status criteria. The investigational drug TSN1611, an oral small molecule inhibitor targeting both active and inactive forms of KRAS G12D, is administered as monotherapy.
ClinicalTrials.gov ID: NCT06385925
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors or designated lymphomas (with confirmed CD161 expression) who have failed or are intolerant to standard therapies, to receive the investigational anti-CD161 monoclonal antibody IMT-009 (which blocks an inhibitory NK/T cell pathway) as monotherapy or in combination with fruquintinib.
ClinicalTrials.gov ID: NCT05565417
HealthScout AI summary: This trial enrolls adults with unresectable or metastatic solid tumors (including NSCLC, high-grade serous ovarian carcinoma, and uterine serous carcinoma), ECOG 0-1, and at least one accessible lesion for biopsy. Patients receive BMS-986463, a novel investigational antineoplastic agent with an undisclosed mechanism of action, as monotherapy.
ClinicalTrials.gov ID: NCT06476808
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring documented KRAS mutations (excluding prior G12C inhibitor-treated G12C tumors), including NSCLC, CRC, pancreatic, and other KRAS-mutated cancers, who have progressed after standard therapies. Patients receive PF-07985045, a novel oral KRAS inhibitor, as monotherapy or in combination with chemotherapy, targeted agents, or immunotherapy, depending on cohort and tumor type.
ClinicalTrials.gov ID: NCT06704724
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including specific cohorts for EGFR-mutant or wild-type NSCLC, HNSCC, and metastatic CRC—to investigate AZD9592, a bispecific antibody-drug conjugate targeting EGFR and cMET, given alone or in combination with standard therapies such as osimertinib or 5-FU/bevacizumab/leucovorin. Key exclusions are active ILD/pneumonitis, untreated or unstable brain metastases, active infections, or significant cardiac disease.
ClinicalTrials.gov ID: NCT05647122
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors harboring RAS or RAF pathway alterations (including mutations or fusions in KRAS, NRAS, BRAF, CRAF, or NF1) who have progressed after or are intolerant to standard therapies, to receive IK-595, an investigational oral dual MEK/RAF inhibitor designed to inactivate MEK and RAF signaling.
ClinicalTrials.gov ID: NCT06270082
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors that are KRAS G12V-mutant and HLA-A*11:01 positive who have progressed after prior systemic therapy. Patients receive a single infusion of AFNT-211, an autologous T cell therapy engineered to express a TCR targeting HLA-A*11:01/KRAS G12V, following lymphodepleting chemotherapy.
ClinicalTrials.gov ID: NCT06105021
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (and in some cohorts, HER2) exon 20 insertion mutations who have received prior therapy, treating them with STX-721, an investigational oral irreversible tyrosine kinase inhibitor that selectively targets mutant EGFR and HER2.
ClinicalTrials.gov ID: NCT06043817
HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors harboring a KRASG12D mutation (including NSCLC, colorectal, and pancreatic cancers) who have progressed on standard therapy and have not previously received a direct KRAS inhibitor. The trial evaluates AZD0022, a selective oral KRAS G12D inhibitor, as monotherapy and in combination with cetuximab.
ClinicalTrials.gov ID: NCT06599502
